Sixfold Bioscience

Executive Summary

Sixfold Bioscience is a UK-based biotechnology company founded in 2017, addressing a critical bottleneck in RNA therapeutics: systemic delivery to tissues beyond the liver. Unlike conventional lipid nanoparticles, Sixfold's proprietary Mergo® platform leverages AI-designed, unencapsulated RNA structures inspired by natural intercellular transport mechanisms. This approach aims to enable targeted delivery to diverse cell types, potentially unlocking genetic medicines for a wide range of diseases. The company has remained relatively stealthy, with no disclosed funding rounds or partnerships, suggesting it is still in the preclinical or early translational stage. The platform's novelty and potential to overcome a major industry challenge position Sixfold as an intriguing player in the drug delivery space, though validation of its technology in vivo is still awaited. With growing interest in extrahepatic RNA delivery, Sixfold could attract strategic partnerships or Series A funding, driving its next phase of growth.

Upcoming Catalysts (preview)

• Q2 2026Series A or Series B Funding Announcement60% success
• Q3 2026Partnership with a Large Pharma for RNA Delivery Indication40% success
• Q4 2026Preclinical Proof-of-Concept Data Release in a Peer-Reviewed Journal or Conference50% success